Ukrainian Drone Makers Target Japan and Asia Defense Market 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
ANN ARBOR, Mich., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 13, 2016 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.
Esperion’s Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with hypercholesterolemia by developing therapies to lower LDL-C. Esperion scientists discovered ETC-1002 and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both ETC-1002 and a fixed dose combination of ETC-1002 and ezetimibe with a particular focus on patients with hypercholesterolemia who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia. ETC-1002 (bempedoic acid), the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. ETC-1002 inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected] Investor Contact: Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 [email protected]
